Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;22(2):258-267.
doi: 10.1016/j.bbmt.2015.08.025. Epub 2015 Aug 30.

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma

Eric Smith  1 , Sean M Devlin  2 , Satyajit Kosuri  1 , Evelyn Orlando  3 , Heather Landau  4 , Alex M Lesokhin  5 , David J Chung  4 , Hani Hassoun  5 , Nikoletta Lendvai  5 , Ola Landgren  5 , Sergio Giralt  4 , Ajai Chari  6 , Sundar Jagannath  6 , Guenther Koehne  7
Affiliations

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma

Eric Smith et al. Biol Blood Marrow Transplant. 2016 Feb.

Abstract

We report results of a retrospective analysis of 44 patients with relapsed and high-risk multiple myeloma (MM) undergoing allogeneic CD34-selected hematopoietic stem cell transplantation (HSCT) from HLA-compatible donors. Patients had multiply relapsed disease including relapse at <15 months after autologous transplantation and most patients (28 of 44; 65%) also had high-risk cytogenetics. Before transplantation, patients received busulfan (.8 mg/kg × 10 doses), melphalan (70 mg/m(2) × 2 days), fludarabine (25 mg/m(2) × 5 days), and rabbit antithymocyte globulin (2.5 mg/kg × 2 days). Patients with 10/10 HLA- matched donors were treated prophylactically with low doses of donor lymphocyte infusions (.5 to 1 × 10(6) CD3(+)/kg) starting 4 to 6 months after CD34-selected HSCT. Acute (grade II to IV) graft-versus-host disease (GVHD) and transplantation-related mortality at 12 months were 2% and 18%, respectively. Chronic GVHD was not observed in any patient. Overall and progression-free survival at 2 years were 54% and 31%, respectively. By multivariate analyses, the outcomes of CD34-selected HSCT were influenced by presence of extramedullary disease, disease status before CD34-selected HSCT, and age. This study demonstrates notable safety and efficacy of CD34-selected HSCT in patients with multiply relapsed MM, including those with high-risk cytogenetics.

Keywords: Adoptive immunotherapy; D34-selected hematopoietic stem cell transplantation; Relapsed high-risk multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Overall and progression-free survival of 44 patients with multiply relapsed multiple myeloma undergoing CD34-selected HSCT.
Figure 2
Figure 2. Overall and progression-free survival based on lines of treatment prior to CD34-selected HSCT
For these analyses, auto-SCT followed by maintenance therapy and tandem auto-SCT plus maintenance therapy were calculated as a single line of treatment as detailed in Table I.
Figure 3
Figure 3. Overall and progression-free survival based on disease status prior to CD34-selected HSCT
Partial remission (PR) vs very good partial remission (VGPR) / complete remission (CR)
Figure 4
Figure 4
Overall and progression-free survival based on presence (n = 13) or absence (n = 31) of extramedullary manifestation prior to CD34-selected HSCT.
Figure 5
Figure 5. Acute GVHD and non-relapse mortality (NRM)
(A) Acute GVHD (grade II–IV) to days +180 post CD34-selected HSCT, (B) NRM post CD34-selected HSCT and (C), NRM based on disease status (PR; n = 21) or (VGPR/CR; n = 23) prior to CD34-selected HSCT.
See this image and copyright information in PMC

References

    1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860–1873. - PubMed
    1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–2765. - PubMed
    1. Rajkumar S, Fonseca R, Lacy M, et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999;24(5):497–503. - PubMed
    1. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106(8):2837–2840. - PMC - PubMed
    1. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325(18):1267–1273. - PubMed